STAA

STAAR SURGICAL CO - 10-Q Summary (Period Ended June 30, 2000)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2000, and the six-month period ended June 30, 2000, for STAAR SURGICAL COMPANY. The company manufactures and markets intraocular lenses (IOLs) and related ophthalmic products. As of August 8, 2000, there were 15,114,393 shares of common stock outstanding. The company recently announced a significant restructuring plan on June 22, 2000, and underwent executive leadership changes, with John R. Wolf terminated as CEO and William C. Huddleston serving as interim CEO.

Key Financial Metrics

Note: The Net Loss includes significant charges from discontinued operations and restructuring.

Material Changes vs. Prior Period

• Revenue Decline: Revenues decreased 13.0% for the quarter and 8.7% for the six-month period compared to the prior year. This was driven by lower unit sales of IOLs in Asia and Europe and a stronger U.S. dollar, partially offset by new product launches (Toric and Collamer IOLs).
• Margin Compression: Gross margin collapsed from 62.9% to 21.2% for the quarter. This was primarily due to a $5.2 million inventory write-off associated with the restructuring plan.
• Restructuring Charges: The company recorded a pre-tax special charge of approximately $24 million in the second quarter. This included $10.9 million in "Restructuring, impairment, and other nonrecurring charges" on the income statement, plus significant charges in Cost of Sales and Discontinued Operations.
• Discontinued Operations: The company recorded a loss of $6.55 million from discontinued operations, largely due to the write-off of the Japanese joint venture and the exit from the Lasik market.
• Liquidity Deterioration: The current ratio dropped from 2.4:1 to 1.1:1, and net working capital fell from $25.6 million to $2.3 million. This was caused by the reclassification of long-term debt to current liabilities due to covenant violations.

Guidance, Outlook, Risks, and Unusual Items

• Restructuring Plan: The $24 million charge includes $2.0 million in cash severance/exit costs and $19.9 million in non-cash write-downs (inventory, patents, joint venture assets). Management expects cost reduction programs to lower manufacturing costs late in the year or early next year.
• Debt Covenants: The company is not in compliance with restrictive covenants on its primary loan agreement. A forbearance letter has been obtained until September 15, 2000, contingent on maintaining specific financial ratios. The company is seeking alternative financing to pay down the debt, with no assurance of success.
• Legal Proceedings: Significant litigation exists with Canon Inc. regarding the Japanese joint venture. Staar filed a complaint for tortious interference, while Canon filed for arbitration alleging breach of contract. Staar has filed a counterclaim seeking liquidation or transfer of the joint venture.
• Outlook: Management expects to continue to be profitable in the future, relying on cash generated from operations or additional financing.

Investor Verification Checklist

• Debt Refinancing: Verify the status of the company's efforts to secure alternative financing to pay off the current loan agreement before the September 15, 2000 forbearance deadline.
• Restructuring Execution: Confirm the actual cash outflow associated with the $24 million restructuring charge and the timeline for realizing cost savings.
• Canon Litigation: Monitor the progress of the arbitration and counterclaims against Canon Inc., as the resolution could impact the company's international operations and financial position.
• Inventory Levels: Assess the remaining inventory levels post-write-down to ensure future cost of sales margins improve as projected.
• Covenant Compliance: Track the company's ability to meet the financial ratios required by the lender to maintain the forbearance agreement.